However, Blankenburg et al. conducted a study with 240 stage I NSCLC patients (91 AD, 100 SCC, and 32 others) and found that preoperative CEA could not be used to predict the 3- or 5-year OS with a cutoff value of 6.7 ng/mL [22]; in line with this, Maeda et al. performed a study that enrolled 229 stage IA patients (195 AD, 34 others) and suggested that preoperative CEA was not an independent risk factor for poor prognosis [23]. The gene discussed is CEACAM5; the disease is Alzheimer disease.